Author

P. A. Cosgrove

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 5

Signature Assays, Organisms & Methods

Click to filter · or open tag

Organism:human· 5 Research Focus:cell type annotation· 4 Research Focus:differential expression· 4 Approach:experimental assay· 3 Assay:scRNA-seq· 3 Assay:bulk RNA-seq· 2 Research Focus:cell-cell communication· 2 Research Focus:drug response / drug discovery· 2

Frequent Co-Authors

A. H. Bild· 4 shared J. T. Chang· 4 shared A. Nath· 3 shared F. R. Adler· 3 shared J. I. Griffiths· 3 shared J. Chen· 2 shared P. J. Moos· 2 shared Q. J. Khan· 2 shared

Activity by Year

2020-2023 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 37 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

4 shared papersCancer Biology

A. H. Bild

Mutual co-authors in cluster

Author profile →

5 papers

Recent·Most cited

ONC201/TIC10 enhances durability of mTOR inhibitor everolimus in metastatic ER+ breast cancer

E. Farmaki, A. Nath, R. Emond, K. L. Karimi, V. K. Grolmusz, P. A. Cosgrove, A. H. Bild

This study shows that combining ONC201/TIC10 with everolimus improves therapeutic response in metastatic ER+ breast cancer by targeting mitochondrial function and oxidative phosphorylation.

eLife · Sep 29, 2023Peer-reviewedCancer Biology

Cancer cells communicate with macrophages to prevent T cell activation during development of cell cycle therapy resistance

J. I. Griffiths, P. A. Cosgrove, E. Medina Castaneda, A. Nath, J. Chen, F. R. Adler, J. T. Chang, Q. J. Khan, A. H. Bild

The paper shows cancer cells in resistant tumors promote immune-suppressive macrophages, reducing T-cell activation, and suggests balancing cell cycle inhibition with immune activation for better therapy.

bioRxiv · Sep 14, 2022 · PreprintCancer Biology

Convergent evolution of resistance pathways during early stage breast cancer treatment with combination cell cycle (CDK) and endocrine inhibitors

J. I. Griffiths, J. Chen, P. A. Cosgrove, A. O'Dea, P. Sharma, C. Ma, M. Trivedi, K. Kalinsky, K. B. Wisinski, R. O'Regan, , I. Makhoul, L. M. Spring, A. Bardia, F. R. Adler, A. L. Cohen, , A. Bild

This study examines how breast cancer tumors evolve during early stage treatment with combination CDK and endocrine inhibitors, finding convergent resistance pathways and increased subclonal diversity with combination therapy.

bioRxiv · Jan 19, 2021 · PreprintCancer Biology

Circulating immune cell phenotype dynamics reflect the strength of tumor-immune cell interactions in patients during immunotherapy

J. I. Griffiths, P. Wallet, L. T. Pflieger, D. Stenehjem, X. Liu, P. A. Cosgrove, N. A. Leggett, J. McQuerry, G. Shrestha, M. Rossetti, G. Sunga, P. J. Moos, F. R. Adler, J. T. Chang, S. Sharma, A. H. Bild

The paper shows that immune cell dynamics in peripheral blood reflect tumor-immune interactions during immunotherapy, with responder patients showing increased cytotoxic differentiation and interferon signaling.

Proceedings of the National Academy of Sciences · Jun 22, 2020Peer-reviewedCancer Biology

A 'one-two punch' therapy strategy to target chemoresistance in estrogen receptor positive breast cancer

F. Chi, J. Liu, S. W. Brady, P. A. Cosgrove, A. Nath, J. A. McQuerry, S. Majumdar, P. J. Moos, J. T. Chang, M. Kahn, A. H. Bild

This study identifies a sequential therapy strategy using HDAC inhibitors to reverse chemotherapy-induced resistance in ER+ breast cancer by targeting cancer stem cell-like traits.

bioRxiv · Mar 12, 2020Cancer Biology